Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CHINA HEALTH

China Health Technology Group Holding Company Limited
中國健康科技集團控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1069)

(1) APPOINTMENT OF DIRECTORS
(2) CHANGE IN COMPOSITION OF THE BOARD COMMITTEES
(3) COMPLIANCE WITH RULES 3.10 AND 3.21 OF THE LISTING RULES

APPOINTMENT OF EXECUTIVE DIRECTOR

The board (the "**Board**") of directors (the "**Director(s)**") of China Health Technology Group Holding Company Limited (the "**Company**", and together with its subsidiaries, the "**Group**") is pleased to announce that Ms. Cao Xiying ("**Ms. Cao**") has been appointed as an executive Director with effect from 15 January 2026.

Biographic details of Ms. Cao are set out as follows:

Ms. Cao Xiying, aged 32, graduated from Harbin University（哈爾濱學院）in 2015 with a college degree in business administration. Ms. Cao has extensive experience in project management and sales and marketing. She worked as the project manager in Shenzhen Shanhuitong Internet and Finance Services Company Limited*（深圳杉匯通互聯網金融服務有限公司）from 2017 to 2025 and has been working as the operating director of Jinshi Media Technology (Shenzhen) Company Limited*（金石傳媒科技（深圳）有限公司）from 2025 to present.

With respect to her directorship with the Company, Ms. Cao has entered into a contract of appointment with the Company and Ms. Cao will be appointed for a term of one year with an annual remuneration of HK$96,000. The remuneration is recommended by the remuneration committee of the Board (the "**Remuneration Committee**") with reference to the remuneration policy of the Company, her duties and the prevailing market level of remuneration for executives of similar positions. Ms. Cao shall only hold office until the next annual general meeting of the Company but shall be eligible for re-election in accordance with the articles of association of the Company.

As at the date of this announcement and save as disclosed above, Ms. Cao (i) does not hold any directorship or have any major appointment in any listed public company in the last three years preceding the date of this appointment and does not have any other major appointments and professional qualifications; (ii) does not have any relationships with any directors, senior management or substantial or controlling shareholders of the Company and has not held any other positions with any other members of the Group; and (iii) does not have any interest in the shares or underlying shares of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "**SFO**").

Save as disclosed above, the Board is not aware of other matters relating to the appointment of Ms. Cao that need to be brought to the attention of the shareholders of the Company and there is no other information which is required to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**").

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that Mr. Li Liangjie ("**Mr. Li**") has been appointed as an independent non-executive Director with effect from 15 January 2026.

Biographic details of Mr. Li are set out as follows:

Mr. Li Jiangjie, aged 36, graduated from Henan University of Animal Husbandry and Economy (河南牧業經濟學院) in 2011 with a bachelor degree in e-commerce. Mr. Li has over 15 years of experience in sales management and has over 9 years of experience in online marketing and sales management within the health and wellness sector. He worked as the sales director in Henan Yuhuan Health Technology Group Co., Limited* (河南雲環健康科技集團有限公司) ("**Henan Yuhuan**") from 2016 to present. Henan Yuhuan is a comprehensive enterprise deeply engaged in the health and wellness industry, with business coverage including health consultation, remote health management, as well as supporting services such as marketing planning and brand management. Mr. Li is responsible for building the group's marketing system and overseeing sales management. He has led the integration of online and offline marketing resources and driven the achievement of sales targets.

With respect to his directorship with the Company, Mr. Li has entered into a contract of appointment with the Company and Mr. Li will be appointed for a term of one year with an annual remuneration of HK$36,000. The remuneration is recommended by the Remuneration Committee with reference to the remuneration policy of the Company, his duties and the prevailing market level of remuneration for executives of similar positions. Mr. Li shall only hold office until the next annual general meeting of the Company but shall be eligible for reelection in accordance with the articles of association of the Company.

As at the date of this announcement and save as disclosed above, Mr. Li (i) does not hold any directorship or have any major appointment in any listed public company in the last three years preceding the date of this appointment and does not have any other major appointments and professional qualifications; (ii) does not have any relationships with any directors, senior management or substantial or controlling shareholders of the Company and has not held any other positions with any other members of the Group; and (iii) does not have any interest in the shares or underlying shares of the Company or any of its associated corporations within the meaning of Part XV of the SFO. Mr. Li has further confirmed that (i) he has satisfied the independence criteria set out in Rule 3.13 of the Listing Rules; (ii) he has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected persons of the Company; and (iii) there are no other factors that may affect his independence at the time of her appointment.

Save as disclosed above, the Board is not aware of other matters relating to the appointment of Mr. Li that need to be brought to the attention of the shareholders of the Company and there is no other information which is required to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules.

The Board would like to extend its warmest welcome to Ms. Cao and Mr. Li for their appointment.

CHANGE IN COMPOSITION OF THE BOARD COMMITTEES

The Board also announces the with effect from 15 January 2026, Mr. Li has been appointed as a member of each of the audit committee of the Board (the "**Audit Committee**"), the Remuneration Committee and the nomination committee of the Board.

COMPLIANCE WITH RULE 3.10 AND RULE 3.21 OF THE LISTING RULES

According to Rule 3.10(1) of the Listing Rules, the Company is required to have at least three independent non-executive Directors. According to Rule 3.21 of the Listing Rules, the Audit Committee must comprise a minimum of three members.

Following the appointment Mr. Li,

(1) the Company has three independent non-executive Directors, thus the number of independent non-executive Directors meets the minimum number required under Rule 3.10(1) of the Listing Rules; and

(2) the Audit Committee has three members, thus the number of members meets the minimum number required under Rule 3.21 of the Listing Rules.

By Order of the Board
China Health Technology Group Holding Company Limited
Bu Xue
Chairman and Executive Director

Hong Kong, 15 January 2026

As at the date of this announcement, the Board comprises Ms. Bu Xue and Ms. Cao Xiying as the executive Directors; and Mr. Chau Wing Nam, Ms. Liu Shuhua and Mr. Li Liangjie as the independent non-executive Directors.

* *for identification purposes only*